澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atorvastatin calcium trihydrate, quantity: 86.751 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: sodium carbonate; lactose; microcrystalline cellulose; colloidal anhydrous silica; hyprolose; magnesium stearate; arginine; croscarmellose sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - lorstat is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,lorstat is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1 pharmacodynamic properties, clinical trials) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atorvastatin calcium trihydrate, quantity: 43.376 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: sodium carbonate; magnesium stearate; lactose; hyprolose; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; arginine; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - lorstat is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,lorstat is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1 pharmacodynamic properties, clinical trials) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atorvastatin calcium trihydrate, quantity: 21.688 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: arginine; hyprolose; colloidal anhydrous silica; lactose; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; sodium carbonate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - lorstat is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,lorstat is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1 pharmacodynamic properties, clinical trials) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atorvastatin calcium trihydrate, quantity: 10.844 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; microcrystalline cellulose; lactose; sodium carbonate; arginine; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - lorstat is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,lorstat is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (section 5.1 pharmacodynamic properties, clinical trials) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

美国 - 英文 - NLM (National Library of Medicine)

physicians total care, inc. - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - pioglitazone hydrochloride 15 mg - actoplus met is a thiazolidinedione and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and metformin or who have inadequate glycemic control on a thiazolidinedione alone or metformin alone. initiation of actoplus met in patients with established new york heart association (nyha) class iii or iv heart failure is contraindicated (see boxed warning ). in addition, actoplus met is contraindicated in patients with: - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 mg/dl [males], ≥ 1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings, metformin hydrochloride and precautions, general: metformin hydrochloride ). - known hypersensitivity to pioglitazone, metformin or any other component of actop

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fosinopril sodium; hydrochlorothiazide -

欧盟 - 英文 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.micardisplus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.micardisplus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on micardisplus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

欧盟 - 英文 - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - breast neoplasms - endocrine therapy - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - difelikefalin acetate, quantity: 55 microgram (equivalent: difelikefalin, qty 50 microgram) - injection, solution - excipient ingredients: sodium chloride; sodium acetate trihydrate; acetic acid; water for injections - korsuva is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

美国 - 英文 - NLM (National Library of Medicine)

stemline therapeutics, inc. - elacestrant (unii: fm6a2627a8) (elacestrant - unii:fm6a2627a8) - orserdu is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (er)-positive, human epidermal growth factor receptor 2 (her2)‑negative, esr1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. none. risk summary based on findings in animals and its mechanism of action, orserdu can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available human data on orserdu use in pregnant women to inform the drug-associated risk. in an animal reproduction study, oral administration of elacestrant to pregnant rats during organogenesis caused embryo-fetal mortality and structural abnormalities at maternal exposures below the recommended dose based on auc (see data) . advise pregnant women and females of reproductive potential of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u